TY - JOUR
T1 - Significantly lower annual rates of neoplastic progression in short- compared to long-segment non-dysplastic Barrett's esophagus
T2 - A systematic review and meta-analysis
AU - Chandrasekar, Viveksandeep Thoguluva
AU - Hamade, Nour
AU - Desai, Madhav
AU - Rai, Tarun
AU - Gorrepati, Venkata Subhash
AU - Jegadeesan, Ramprasad
AU - Sathyamurthy, Anjana
AU - Sharma, Prateek
N1 - Publisher Copyright:
© 2019 Georg Thieme Verlag KG Stuttgart New York.
PY - 2019
Y1 - 2019
N2 - Background Although shorter lengths of Barrett's esophagus (BE) have been associated with a lower risk of neoplastic progression, precise estimates have varied, especially for non-dysplastic BE (NDBE) only. Therefore, current US guidelines do not provide specific recommendations on surveillance intervals based on BE length. We performed a systematic review and meta-analysis of the published literature to examine neoplastic progression rates of NDBE based on BE length. Methods PubMed, Cochrane, Google Scholar, and Embase were comprehensively searched. Studies reporting progression rates in patients with NDBE and > 1 year of follow-up were included. The number of patients progressing to esophageal adenocarcinoma (EAC) and high grade dysplasia (HGD)/EAC in individual studies and the mean follow-up were recorded to derive person-years of follow-up. Pooled rates of progression to EAC and HGD/EAC based on BE length (< 3 cm vs. ≥ 3 cm) were calculated. Results Of the 486 initial studies identified, 10 met the inclusion/exclusion criteria. These included a total of 4097 NDBE patients; 1979 with short-segment BE (SSBE; 10 773 person-years of follow-up) and 2118 with long-segment BE (LSBE; 12 868 person-years). The annual rates of progression to EAC were significantly lower for SSBE compared with LSBE: 0.06 % (95 % confidence interval 0.01 % - 0.10 %) vs. 0.31 % (0.21 % - 0.40 %), respectively; odds ratio (OR) 0.25 (0.11 - 0.56); P < 0.001, as were the rates for the combined endpoint (HGD/EAC): 0.24 % (0.09 % - 0.32 %) vs. 0.76 % (0.43 % - 0.89 %), respectively; OR 0.35 (0.21 - 0.58); P < 0.001. There was no significant heterogeneity among studies. Conclusion The results demonstrate significantly lower rates of neoplastic progression in NDBE patients with SSBE compared with LSBE. BE length can easily be used for risk stratification purposes for NDBE patients undergoing surveillance endoscopy and consideration should be given to tailoring surveillance intervals based on BE length in future US guidelines.
AB - Background Although shorter lengths of Barrett's esophagus (BE) have been associated with a lower risk of neoplastic progression, precise estimates have varied, especially for non-dysplastic BE (NDBE) only. Therefore, current US guidelines do not provide specific recommendations on surveillance intervals based on BE length. We performed a systematic review and meta-analysis of the published literature to examine neoplastic progression rates of NDBE based on BE length. Methods PubMed, Cochrane, Google Scholar, and Embase were comprehensively searched. Studies reporting progression rates in patients with NDBE and > 1 year of follow-up were included. The number of patients progressing to esophageal adenocarcinoma (EAC) and high grade dysplasia (HGD)/EAC in individual studies and the mean follow-up were recorded to derive person-years of follow-up. Pooled rates of progression to EAC and HGD/EAC based on BE length (< 3 cm vs. ≥ 3 cm) were calculated. Results Of the 486 initial studies identified, 10 met the inclusion/exclusion criteria. These included a total of 4097 NDBE patients; 1979 with short-segment BE (SSBE; 10 773 person-years of follow-up) and 2118 with long-segment BE (LSBE; 12 868 person-years). The annual rates of progression to EAC were significantly lower for SSBE compared with LSBE: 0.06 % (95 % confidence interval 0.01 % - 0.10 %) vs. 0.31 % (0.21 % - 0.40 %), respectively; odds ratio (OR) 0.25 (0.11 - 0.56); P < 0.001, as were the rates for the combined endpoint (HGD/EAC): 0.24 % (0.09 % - 0.32 %) vs. 0.76 % (0.43 % - 0.89 %), respectively; OR 0.35 (0.21 - 0.58); P < 0.001. There was no significant heterogeneity among studies. Conclusion The results demonstrate significantly lower rates of neoplastic progression in NDBE patients with SSBE compared with LSBE. BE length can easily be used for risk stratification purposes for NDBE patients undergoing surveillance endoscopy and consideration should be given to tailoring surveillance intervals based on BE length in future US guidelines.
UR - http://www.scopus.com/inward/record.url?scp=85068223040&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068223040&partnerID=8YFLogxK
U2 - 10.1055/a-0869-7960
DO - 10.1055/a-0869-7960
M3 - Review article
C2 - 30939618
AN - SCOPUS:85068223040
SN - 0013-726X
VL - 51
SP - 665
EP - 672
JO - Endoscopy
JF - Endoscopy
IS - 7
ER -